Intellia Therapeutics (NTLA) Completes Phase 3 Enrollment As Investors Ask If It Is Still A Bargain

Intellia Therapeutics (NTLA) just reached a key pipeline checkpoint by completing enrollment in its MAGNITUDE-2 Phase 3 trial for nex-z in hereditary transthyretin amyloidosis with polyneuropathy, an area of focus for gene-editing investors.

Despite the pipeline milestone, Intellia Therapeutics’ latest share price of $11.17 reflects short term pressure, with the stock down 7.76% on a 1 day share price basis and 14.54% over 30 days, while the year to date share price return of 21.28% contrasts with a 5 year total shareholder return decline of 91.88%. This indicates that recent momentum has picked up from a low base as investors weigh fresh MAGNITUDE data, earnings updates and upcoming conference presentations against a long history of weak overall investor outcomes.

Capitalize on the gene editing theme by scanning a curated set of 36 healthcare AI stocks that, like Intellia Therapeutics, sit at the intersection of cutting-edge biology and advanced computation.

After a sharp bounce off long term lows, Intellia Therapeutics now forces a simple choice. Is most of the easy upside already spent, or is the rerating only just beginning once you look at the valuation work.

Most Popular Narrative: 52% Undervalued

On the analyst consensus Narrative on Simply Wall St, Intellia Therapeutics screens as materially undervalued, with a fair value of $23.11 against the last close at $11.17, which puts the current share price at a steep discount before any pipeline news is priced in.

The current valuation implies that Intellia Therapeutics is undervalued relative to the potential cash runway into at least 2028, the large rare disease pricing multiples discussed for lonvo z, and the upside some research firms see if nex z proves additive on top of current ATTR standards of care.

See why 91 investors see Intellia Therapeutics as 52% undervalued.

Result: Fair Value of $23.11 (UNDERVALUED)

Still, the Intellia Therapeutics story could change significantly if key trials struggle with safety questions or if payers push back hard on high one-time pricing.

Find out about the key risks to this Intellia Therapeutics narrative.

Another Take on Intellia Therapeutics’ Valuation

On earnings style ratios, Intellia Therapeutics looks cheap. Our DCF model paints an even more aggressive picture, with an estimated future cash flow value of $265.25 against a share price of $11.17. That gap suggests a substantial difference on paper, but how comfortable are you with the assumptions doing the heavy lifting?

Look into how the SWS DCF model arrives at its fair value.

Next Steps

Mixed signals around Intellia Therapeutics can pull you in either direction, so move quickly, review the data and weigh both the 2 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Intellia Therapeutics?

If Intellia Therapeutics has your attention, do not stop here. Broaden your watchlist with focused ideas that match your risk comfort and return goals.

• Target potential bargains by scanning companies that appear mispriced on fundamentals through the 35 high quality undervalued stocks.
• Prioritise resilience by reviewing the 30 resilient stocks with low risk scores and concentrate on businesses with steadier profiles when markets turn choppy.
• Spot possible future outperformers early by combing through the 20 high quality undiscovered gems before the wider market catches on.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com